Aditx Therapeutics (ADTX)
(Delayed Data from NSDQ)
$2.09 USD
+0.08 (3.98%)
Updated May 20, 2024 03:59 PM ET
After-Market: $2.01 -0.08 (-3.83%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Price, Consensus and EPS Surprise
ADTX 2.09 +0.08(3.98%)
Will ADTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ADTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADTX
Indivior PLC (INDV) Tops Q3 Earnings and Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue Estimates
ADTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harpoon Therapeutics, Inc. (HARP) Beats Q2 Earnings and Revenue Estimates
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Is the Options Market Predicting a Spike in Aditx (ADTX) Stock?
Other News for ADTX
ADTX Stock Earnings: Aditxt Reported Results for Q1 2024
Aditxt prices $4.2M private placement
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
Aditxt, Inc. Merger with Evofem Biosciences Falls Through
Aditxt, Inc. Announces Strategic Acquisition of Appili Therapeutics